Group 1 - The core product of the company, the TROP2-targeted antibody-drug conjugate (ADC) sac-TMT, has received approval from the National Medical Products Administration (NMPA) in China for its fourth indication, aimed at treating adult patients with HR+/HER2- breast cancer who have previously undergone endocrine therapy and at least one line of chemotherapy in the advanced disease stage [1][2] - The approval is based on positive results from the OptiTROP-Breast02 Phase 3 clinical study, which has been selected for a breakthrough abstract presentation at the 2025 European Society for Medical Oncology (ESMO) conference [1] Group 2 - The company has renewed a framework agreement with China Resources Kolun for research and development-related materials, extending until 2026 [2]
科伦博泰生物-B(06990.HK)：核心产品TROP2ADC芦康沙妥珠单抗(sac-TMT)获国家药监局批准第四项适应症上市，用于治疗2L+HR+/HER2-乳腺癌